West Pharmaceutical Services, Inc. (NYSE: WST) Stock Competitors & Peer Comparison
See WST's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for WST and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| WST | $361.98 | +1.91% | 25.7B | 42.93 | $8.50 | +0.24% |
| ISRG | $385.13 | +1.90% | 133.2B | 39.21 | $9.62 | N/A |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.13% |
| BDX | $184.20 | +0.71% | 51.2B | 14.30 | $13.00 | +2.13% |
| RMD | $227.67 | +2.10% | 33.3B | 21.32 | $10.77 | +1.06% |
| MDLN | $33.50 | +2.78% | 27.2B | 23.53 | $1.36 | N/A |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| SOLV | $90.53 | +0.79% | 15.6B | 12.69 | $7.10 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.13% |
| BAX | $23.52 | -1.42% | 12.3B | 11.39 | $2.08 | +0.17% |
Stock Comparison
Intuitive Surgical, Inc. (NASDAQ: ISRG)
WST vs ISRG Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, ISRG has a market cap of 133.2B. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while ISRG trades at $385.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas ISRG's P/E ratio is 39.21. In terms of profitability, WST's ROE is +0.19%, compared to ISRG's ROE of +0.18%. Regarding short-term risk, WST is less volatile compared to ISRG. This indicates lower risk in terms of short-term price fluctuations for WST.Check ISRG's competition here
Becton, Dickinson and Company (NYSE: BDXA)
WST vs BDXA Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas BDXA's P/E ratio is 45.70. In terms of profitability, WST's ROE is +0.19%, compared to BDXA's ROE of +0.04%. Regarding short-term risk, WST is less volatile compared to BDXA. This indicates lower risk in terms of short-term price fluctuations for WST.Check BDXA's competition here
Becton, Dickinson and Company (NYSE: BDX)
WST vs BDX Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, BDX has a market cap of 51.2B. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while BDX trades at $184.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas BDX's P/E ratio is 14.30. In terms of profitability, WST's ROE is +0.19%, compared to BDX's ROE of +0.04%. Regarding short-term risk, WST is more volatile compared to BDX. This indicates higher risk in terms of short-term price fluctuations for WST.Check BDX's competition here
ResMed Inc. (NYSE: RMD)
WST vs RMD Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, RMD has a market cap of 33.3B. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while RMD trades at $227.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas RMD's P/E ratio is 21.32. In terms of profitability, WST's ROE is +0.19%, compared to RMD's ROE of +0.24%. Regarding short-term risk, WST is less volatile compared to RMD. This indicates lower risk in terms of short-term price fluctuations for WST.Check RMD's competition here
Medline Inc. (NASDAQ: MDLN)
WST vs MDLN Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, MDLN has a market cap of 27.2B. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while MDLN trades at $33.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas MDLN's P/E ratio is 23.53. In terms of profitability, WST's ROE is +0.19%, compared to MDLN's ROE of +0.05%. Regarding short-term risk, WST is less volatile compared to MDLN. This indicates lower risk in terms of short-term price fluctuations for WST.Check MDLN's competition here
Hologic, Inc. (NASDAQ: HOLX)
WST vs HOLX Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas HOLX's P/E ratio is 31.54. In terms of profitability, WST's ROE is +0.19%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, WST is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for WST.Check HOLX's competition here
Solventum Corporation (NYSE: SOLV)
WST vs SOLV Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, SOLV has a market cap of 15.6B. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while SOLV trades at $90.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas SOLV's P/E ratio is 12.69. In terms of profitability, WST's ROE is +0.19%, compared to SOLV's ROE of +0.29%. Regarding short-term risk, WST is less volatile compared to SOLV. This indicates lower risk in terms of short-term price fluctuations for WST.Check SOLV's competition here
Becton, Dickinson and Company (NYSE: BDXB)
WST vs BDXB Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas BDXB's P/E ratio is 7.60. In terms of profitability, WST's ROE is +0.19%, compared to BDXB's ROE of +0.04%. Regarding short-term risk, WST is less volatile compared to BDXB. This indicates lower risk in terms of short-term price fluctuations for WST.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
WST vs BAX Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, BAX has a market cap of 12.3B. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while BAX trades at $23.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas BAX's P/E ratio is 11.39. In terms of profitability, WST's ROE is +0.19%, compared to BAX's ROE of -0.17%. Regarding short-term risk, WST is less volatile compared to BAX. This indicates lower risk in terms of short-term price fluctuations for WST.Check BAX's competition here
Avantor, Inc. (NYSE: AVTR)
WST vs AVTR Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, AVTR has a market cap of 10.4B. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while AVTR trades at $15.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas AVTR's P/E ratio is 18.15. In terms of profitability, WST's ROE is +0.19%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, WST is less volatile compared to AVTR. This indicates lower risk in terms of short-term price fluctuations for WST.Check AVTR's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
WST vs COO Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, COO has a market cap of 10.4B. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while COO trades at $54.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas COO's P/E ratio is 11.68. In terms of profitability, WST's ROE is +0.19%, compared to COO's ROE of +0.07%. Regarding short-term risk, WST is less volatile compared to COO. This indicates lower risk in terms of short-term price fluctuations for WST.Check COO's competition here
Repligen Corporation (NASDAQ: RGEN)
WST vs RGEN Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, RGEN has a market cap of 9.9B. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while RGEN trades at $174.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas RGEN's P/E ratio is 97.07. In terms of profitability, WST's ROE is +0.19%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, WST is less volatile compared to RGEN. This indicates lower risk in terms of short-term price fluctuations for WST.Check RGEN's competition here
AptarGroup, Inc. (NYSE: ATR)
WST vs ATR Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, ATR has a market cap of 8B. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while ATR trades at $125.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas ATR's P/E ratio is 21.79. In terms of profitability, WST's ROE is +0.19%, compared to ATR's ROE of +0.14%. Regarding short-term risk, WST is more volatile compared to ATR. This indicates higher risk in terms of short-term price fluctuations for WST.Check ATR's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
WST vs BLCO Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, BLCO has a market cap of 6.2B. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while BLCO trades at $17.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas BLCO's P/E ratio is 26.52. In terms of profitability, WST's ROE is +0.19%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, WST is more volatile compared to BLCO. This indicates higher risk in terms of short-term price fluctuations for WST.Check BLCO's competition here
Stevanato Group S.p.A. (NYSE: STVN)
WST vs STVN Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, STVN has a market cap of 5.9B. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while STVN trades at $21.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas STVN's P/E ratio is 32.57. In terms of profitability, WST's ROE is +0.19%, compared to STVN's ROE of +0.09%. Regarding short-term risk, WST is less volatile compared to STVN. This indicates lower risk in terms of short-term price fluctuations for WST.Check STVN's competition here
Teleflex Incorporated (NYSE: TFX)
WST vs TFX Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, TFX has a market cap of 5.7B. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while TFX trades at $129.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas TFX's P/E ratio is 14.75. In terms of profitability, WST's ROE is +0.19%, compared to TFX's ROE of -0.32%. Regarding short-term risk, WST is more volatile compared to TFX. This indicates higher risk in terms of short-term price fluctuations for WST.Check TFX's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
WST vs MMSI Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, MMSI has a market cap of 5.1B. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while MMSI trades at $86.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas MMSI's P/E ratio is 22.04. In terms of profitability, WST's ROE is +0.19%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, WST is less volatile compared to MMSI. This indicates lower risk in terms of short-term price fluctuations for WST.Check MMSI's competition here
Envista Holdings Corp (NYSE: NVST)
WST vs NVST Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, NVST has a market cap of 4B. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while NVST trades at $25.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas NVST's P/E ratio is 16.85. In terms of profitability, WST's ROE is +0.19%, compared to NVST's ROE of +0.04%. Regarding short-term risk, WST is less volatile compared to NVST. This indicates lower risk in terms of short-term price fluctuations for WST.Check NVST's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
WST vs ICUI Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, ICUI has a market cap of 3.9B. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while ICUI trades at $158.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas ICUI's P/E ratio is 19.46. In terms of profitability, WST's ROE is +0.19%, compared to ICUI's ROE of +0.01%. Regarding short-term risk, WST is more volatile compared to ICUI. This indicates higher risk in terms of short-term price fluctuations for WST.Check ICUI's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
WST vs PLSE Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, PLSE has a market cap of 3.8B. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while PLSE trades at $49.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas PLSE's P/E ratio is -46.78. In terms of profitability, WST's ROE is +0.19%, compared to PLSE's ROE of -0.94%. Regarding short-term risk, WST is less volatile compared to PLSE. This indicates lower risk in terms of short-term price fluctuations for WST.Check PLSE's competition here
AtriCure, Inc. (NASDAQ: ATRC)
WST vs ATRC Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, ATRC has a market cap of 2.9B. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while ATRC trades at $56.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas ATRC's P/E ratio is 1745.96. In terms of profitability, WST's ROE is +0.19%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, WST is less volatile compared to ATRC. This indicates lower risk in terms of short-term price fluctuations for WST.Check ATRC's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
WST vs XRAY Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, XRAY has a market cap of 2B. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while XRAY trades at $10.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas XRAY's P/E ratio is 6.87. In terms of profitability, WST's ROE is +0.19%, compared to XRAY's ROE of -0.40%. Regarding short-term risk, WST is less volatile compared to XRAY. This indicates lower risk in terms of short-term price fluctuations for WST.Check XRAY's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
WST vs LMAT Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, LMAT has a market cap of 1.8B. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while LMAT trades at $80.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas LMAT's P/E ratio is 29.69. In terms of profitability, WST's ROE is +0.19%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, WST is more volatile compared to LMAT. This indicates higher risk in terms of short-term price fluctuations for WST.Check LMAT's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
WST vs BLFS Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, BLFS has a market cap of 1.8B. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while BLFS trades at $36.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas BLFS's P/E ratio is -172.18. In terms of profitability, WST's ROE is +0.19%, compared to BLFS's ROE of +0.13%. Regarding short-term risk, WST is less volatile compared to BLFS. This indicates lower risk in terms of short-term price fluctuations for WST.Check BLFS's competition here
Azenta, Inc. (NASDAQ: AZTA)
WST vs AZTA Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, AZTA has a market cap of 1.5B. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while AZTA trades at $33.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas AZTA's P/E ratio is 78.64. In terms of profitability, WST's ROE is +0.19%, compared to AZTA's ROE of -0.08%. Regarding short-term risk, WST is less volatile compared to AZTA. This indicates lower risk in terms of short-term price fluctuations for WST.Check AZTA's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
WST vs KMTS Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, KMTS has a market cap of 1.5B. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while KMTS trades at $24.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas KMTS's P/E ratio is -9.50. In terms of profitability, WST's ROE is +0.19%, compared to KMTS's ROE of -0.64%. Regarding short-term risk, WST is less volatile compared to KMTS. This indicates lower risk in terms of short-term price fluctuations for WST.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
WST vs STAA Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, STAA has a market cap of 1.1B. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while STAA trades at $22.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas STAA's P/E ratio is 39.38. In terms of profitability, WST's ROE is +0.19%, compared to STAA's ROE of +0.01%. Regarding short-term risk, WST is less volatile compared to STAA. This indicates lower risk in terms of short-term price fluctuations for WST.Check STAA's competition here
Atrion Corporation (NASDAQ: ATRI)
WST vs ATRI Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas ATRI's P/E ratio is 64.50. In terms of profitability, WST's ROE is +0.19%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, WST is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for WST.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
WST vs ANGO Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, ANGO has a market cap of 648.1M. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while ANGO trades at $15.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas ANGO's P/E ratio is -40.21. In terms of profitability, WST's ROE is +0.19%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, WST is more volatile compared to ANGO. This indicates higher risk in terms of short-term price fluctuations for WST.Check ANGO's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
WST vs SMTI Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, SMTI has a market cap of 322.8M. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while SMTI trades at $35.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas SMTI's P/E ratio is -585.17. In terms of profitability, WST's ROE is +0.19%, compared to SMTI's ROE of -4.74%. Regarding short-term risk, WST is more volatile compared to SMTI. This indicates higher risk in terms of short-term price fluctuations for WST.Check SMTI's competition here
Embecta Corp. (NASDAQ: EMBC)
WST vs EMBC Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, EMBC has a market cap of 302M. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while EMBC trades at $5.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas EMBC's P/E ratio is 1.96. In terms of profitability, WST's ROE is +0.19%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, WST is less volatile compared to EMBC. This indicates lower risk in terms of short-term price fluctuations for WST.Check EMBC's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
WST vs NNNN Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, NNNN has a market cap of 241.8M. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while NNNN trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas NNNN's P/E ratio is 79.62. In terms of profitability, WST's ROE is +0.19%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, WST is less volatile compared to NNNN. This indicates lower risk in terms of short-term price fluctuations for WST.Check NNNN's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
WST vs OSUR Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, OSUR has a market cap of 238.2M. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while OSUR trades at $3.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas OSUR's P/E ratio is -5.01. In terms of profitability, WST's ROE is +0.19%, compared to OSUR's ROE of -0.15%. Regarding short-term risk, WST is less volatile compared to OSUR. This indicates lower risk in terms of short-term price fluctuations for WST.Check OSUR's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
WST vs UTMD Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, UTMD has a market cap of 237.6M. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while UTMD trades at $74.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas UTMD's P/E ratio is 22.08. In terms of profitability, WST's ROE is +0.19%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, WST is more volatile compared to UTMD. This indicates higher risk in terms of short-term price fluctuations for WST.Check UTMD's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
WST vs PDEX Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, PDEX has a market cap of 213.6M. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while PDEX trades at $72.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas PDEX's P/E ratio is 16.20. In terms of profitability, WST's ROE is +0.19%, compared to PDEX's ROE of +0.31%. Regarding short-term risk, WST is less volatile compared to PDEX. This indicates lower risk in terms of short-term price fluctuations for WST.Check PDEX's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
WST vs KRMD Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, KRMD has a market cap of 145.1M. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while KRMD trades at $3.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas KRMD's P/E ratio is -79.00. In terms of profitability, WST's ROE is +0.19%, compared to KRMD's ROE of -0.11%. Regarding short-term risk, WST is less volatile compared to KRMD. This indicates lower risk in terms of short-term price fluctuations for WST.Check KRMD's competition here
Stereotaxis, Inc. (AMEX: STXS)
WST vs STXS Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, STXS has a market cap of 129.3M. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while STXS trades at $1.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas STXS's P/E ratio is -7.76. In terms of profitability, WST's ROE is +0.19%, compared to STXS's ROE of -1.33%. Regarding short-term risk, WST is less volatile compared to STXS. This indicates lower risk in terms of short-term price fluctuations for WST.Check STXS's competition here
Daxor Corporation (NASDAQ: DXR)
WST vs DXR Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, DXR has a market cap of 68M. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while DXR trades at $11.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas DXR's P/E ratio is 9.47. In terms of profitability, WST's ROE is +0.19%, compared to DXR's ROE of +0.13%. Regarding short-term risk, WST is less volatile compared to DXR. This indicates lower risk in terms of short-term price fluctuations for WST.Check DXR's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
WST vs AKYA Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas AKYA's P/E ratio is -1.34. In terms of profitability, WST's ROE is +0.19%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, WST is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for WST.Check AKYA's competition here
SkyAI, Inc. (NASDAQ: STSS)
WST vs STSS Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, STSS has a market cap of 53.7M. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while STSS trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas STSS's P/E ratio is -0.02. In terms of profitability, WST's ROE is +0.19%, compared to STSS's ROE of -1.54%. Regarding short-term risk, WST is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for WST.Check STSS's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
WST vs OMIC Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas OMIC's P/E ratio is -0.58. In terms of profitability, WST's ROE is +0.19%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, WST is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for WST.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
WST vs IGAP Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas IGAP's P/E ratio is -10.52. In terms of profitability, WST's ROE is +0.19%, compared to IGAP's ROE of +1.80%. Regarding short-term risk, WST is less volatile compared to IGAP. This indicates lower risk in terms of short-term price fluctuations for WST.Check IGAP's competition here
Nephros, Inc. (NASDAQ: NEPH)
WST vs NEPH Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, NEPH has a market cap of 46.6M. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while NEPH trades at $4.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas NEPH's P/E ratio is 71.50. In terms of profitability, WST's ROE is +0.19%, compared to NEPH's ROE of +0.16%. Regarding short-term risk, WST is less volatile compared to NEPH. This indicates lower risk in terms of short-term price fluctuations for WST.Check NEPH's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
WST vs POCI Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, POCI has a market cap of 46.1M. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while POCI trades at $4.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas POCI's P/E ratio is -6.68. In terms of profitability, WST's ROE is +0.19%, compared to POCI's ROE of -0.37%. Regarding short-term risk, WST is less volatile compared to POCI. This indicates lower risk in terms of short-term price fluctuations for WST.Check POCI's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
WST vs HBIO Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, HBIO has a market cap of 36M. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while HBIO trades at $8.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas HBIO's P/E ratio is -22.17. In terms of profitability, WST's ROE is +0.19%, compared to HBIO's ROE of -0.92%. Regarding short-term risk, WST is more volatile compared to HBIO. This indicates higher risk in terms of short-term price fluctuations for WST.Check HBIO's competition here
Milestone Scientific Inc. (AMEX: MLSS)
WST vs MLSS Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, MLSS has a market cap of 35.5M. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while MLSS trades at $0.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas MLSS's P/E ratio is -8.02. In terms of profitability, WST's ROE is +0.19%, compared to MLSS's ROE of -1.49%. Regarding short-term risk, WST is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for WST.Check MLSS's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
WST vs SDC Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas SDC's P/E ratio is -0.03. In terms of profitability, WST's ROE is +0.19%, compared to SDC's ROE of -1.96%. Regarding short-term risk, WST is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for WST.Check SDC's competition here
Invacare Corporation (NYSE: IVC)
WST vs IVC Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas IVC's P/E ratio is -0.79. In terms of profitability, WST's ROE is +0.19%, compared to IVC's ROE of -0.46%. Regarding short-term risk, WST is less volatile compared to IVC. This indicates lower risk in terms of short-term price fluctuations for WST.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
WST vs RVP Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, RVP has a market cap of 20.4M. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while RVP trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas RVP's P/E ratio is -5.67. In terms of profitability, WST's ROE is +0.19%, compared to RVP's ROE of -0.05%. Regarding short-term risk, WST is less volatile compared to RVP. This indicates lower risk in terms of short-term price fluctuations for WST.Check RVP's competition here
Bionano Genomics, Inc. (NASDAQ: BNGO)
WST vs BNGO Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, BNGO has a market cap of 17.9M. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while BNGO trades at $1.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas BNGO's P/E ratio is -0.36. In terms of profitability, WST's ROE is +0.19%, compared to BNGO's ROE of -0.79%. Regarding short-term risk, WST is less volatile compared to BNGO. This indicates lower risk in terms of short-term price fluctuations for WST.Check BNGO's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
WST vs ZJYL Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, ZJYL has a market cap of 15.6M. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while ZJYL trades at $1.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas ZJYL's P/E ratio is 13.61. In terms of profitability, WST's ROE is +0.19%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, WST is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for WST.Check ZJYL's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
WST vs RGNT Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, RGNT has a market cap of 12.6M. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while RGNT trades at $1.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas RGNT's P/E ratio is -0.07. In terms of profitability, WST's ROE is +0.19%, compared to RGNT's ROE of N/A. Regarding short-term risk, WST is less volatile compared to RGNT. This indicates lower risk in terms of short-term price fluctuations for WST.Check RGNT's competition here
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (NASDAQ: CUPR)
WST vs CUPR Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, CUPR has a market cap of 7.9M. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while CUPR trades at $1.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas CUPR's P/E ratio is -2.12. In terms of profitability, WST's ROE is +0.19%, compared to CUPR's ROE of -15.69%. Regarding short-term risk, WST is less volatile compared to CUPR. This indicates lower risk in terms of short-term price fluctuations for WST.Check CUPR's competition here
Femasys Inc. (NASDAQ: FEMY)
WST vs FEMY Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, FEMY has a market cap of 7.7M. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while FEMY trades at $2.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas FEMY's P/E ratio is -0.57. In terms of profitability, WST's ROE is +0.19%, compared to FEMY's ROE of -2.26%. Regarding short-term risk, WST is less volatile compared to FEMY. This indicates lower risk in terms of short-term price fluctuations for WST.Check FEMY's competition here
Lucyd, Inc (NASDAQ: LUCY)
WST vs LUCY Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, LUCY has a market cap of 5.2M. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while LUCY trades at $0.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas LUCY's P/E ratio is -0.49. In terms of profitability, WST's ROE is +0.19%, compared to LUCY's ROE of -0.89%. Regarding short-term risk, WST is less volatile compared to LUCY. This indicates lower risk in terms of short-term price fluctuations for WST.Check LUCY's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
WST vs NSTG Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas NSTG's P/E ratio is -0.03. In terms of profitability, WST's ROE is +0.19%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, WST is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for WST.Check NSTG's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
WST vs POAI Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas POAI's P/E ratio is -0.03. In terms of profitability, WST's ROE is +0.19%, compared to POAI's ROE of -21.19%. Regarding short-term risk, WST is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for WST.Check POAI's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
WST vs MHUA Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas MHUA's P/E ratio is 0.25. In terms of profitability, WST's ROE is +0.19%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, WST is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for WST.Check MHUA's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
WST vs NXGL Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, NXGL has a market cap of 2.4M. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while NXGL trades at $0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas NXGL's P/E ratio is -0.40. In terms of profitability, WST's ROE is +0.19%, compared to NXGL's ROE of -1.33%. Regarding short-term risk, WST is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for WST.Check NXGL's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
WST vs GMVD Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas GMVD's P/E ratio is -0.01. In terms of profitability, WST's ROE is +0.19%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, WST is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for WST.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
WST vs GMVDW Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas GMVDW's P/E ratio is N/A. In terms of profitability, WST's ROE is +0.19%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, WST is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for WST.Check GMVDW's competition here
Avinger, Inc. (NASDAQ: AVGR)
WST vs AVGR Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas AVGR's P/E ratio is -0.05. In terms of profitability, WST's ROE is +0.19%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, WST is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for WST.Check AVGR's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
WST vs NXGLW Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, NXGLW has a market cap of 1.2M. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while NXGLW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas NXGLW's P/E ratio is -0.02. In terms of profitability, WST's ROE is +0.19%, compared to NXGLW's ROE of -1.33%. Regarding short-term risk, WST is less volatile compared to NXGLW. This indicates lower risk in terms of short-term price fluctuations for WST.Check NXGLW's competition here
Lucyd, Inc (NASDAQ: LUCYW)
WST vs LUCYW Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas LUCYW's P/E ratio is N/A. In terms of profitability, WST's ROE is +0.19%, compared to LUCYW's ROE of -0.89%. Regarding short-term risk, WST is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for WST.Check LUCYW's competition here
IntriCon Corporation (NASDAQ: IIN)
WST vs IIN Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, IIN has a market cap of 0. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas IIN's P/E ratio is 226.45. In terms of profitability, WST's ROE is +0.19%, compared to IIN's ROE of -0.00%. Regarding short-term risk, WST is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for WST.Check IIN's competition here
Analogic Corporation (NASDAQ: ALOG)
WST vs ALOG Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, ALOG has a market cap of 0. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas ALOG's P/E ratio is 40.93. In terms of profitability, WST's ROE is +0.19%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, WST is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for WST.Check ALOG's competition here
Apria, Inc. (NASDAQ: APR)
WST vs APR Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, APR has a market cap of 0. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas APR's P/E ratio is 22.59. In terms of profitability, WST's ROE is +0.19%, compared to APR's ROE of +9.81%. Regarding short-term risk, WST is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for WST.Check APR's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
WST vs ATRS Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, ATRS has a market cap of 0. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas ATRS's P/E ratio is 14.95. In terms of profitability, WST's ROE is +0.19%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, WST is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for WST.Check ATRS's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
WST vs HRC Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, HRC has a market cap of 0. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas HRC's P/E ratio is 41.92. In terms of profitability, WST's ROE is +0.19%, compared to HRC's ROE of +0.14%. Regarding short-term risk, WST is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for WST.Check HRC's competition here
Invuity, Inc. (NASDAQ: IVTY)
WST vs IVTY Comparison September 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 25.7B. In comparison, IVTY has a market cap of 0. Regarding current trading prices, WST is priced at $361.98 on the NYSE, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 42.93, whereas IVTY's P/E ratio is -3.80. In terms of profitability, WST's ROE is +0.19%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, WST is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for WST.Check IVTY's competition here